<DOC>
	<DOC>NCT01689610</DOC>
	<brief_summary>The purpose of this non-interventional study is to collect data on the efficacy and safety of Nab-Paclitaxel in the routine application.</brief_summary>
	<brief_title>Non-interventional Study With Nab-Paclitaxel (Abraxane®)</brief_title>
	<detailed_description>The main focus of this non-interventional study is set on answering the following questions: - Can the results observed in controlled clinical trials regarding efficacy and safety be reproduced in the routine clinical setting? - Are the side-effects of nab-paclitaxel therapy observed in this study comparable to the previously described safety-profile in terms of frequency and intensity? - What are the main reasons for modification or termination of the nab-paclitaxel therapy? - How does nab-paclitaxel therapy influence the patients' quality of life? - What are the criteria for selecting nab-paclitaxel as therapy for metastatic breast cancer?</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Female Patients with metastatic breast cancer, who are at least 18 years old (no upper age limit) Contraindication according to the summary of product characteristics of Abraxane® No signed patient informed consent form available pregnant or breastfeeding patients.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Nab-Paclitaxel</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Nabucco</keyword>
	<keyword>safety</keyword>
	<keyword>breast cancer</keyword>
	<keyword>daily routine</keyword>
	<keyword>peripheral neuropathy</keyword>
	<keyword>iOMEDICO</keyword>
</DOC>